An open-label, investigator-sponsored, Phase 2 study of ISIS-TTRRx in patients with transthyretin amyloid-related cardiomyopathy which includes patients with familial amyloid cardiomyopathy (FAC) and patients with wild-type transthyretin (wt-TTR) amyloidosis

Trial Profile

An open-label, investigator-sponsored, Phase 2 study of ISIS-TTRRx in patients with transthyretin amyloid-related cardiomyopathy which includes patients with familial amyloid cardiomyopathy (FAC) and patients with wild-type transthyretin (wt-TTR) amyloidosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2016

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloidosis; Cardiomyopathies
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top